$MNPR
Monopar Therapeutics

2022 Q3 Form 10-Q Financial Statement

#000165495422011015 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $675.1K $684.9K $779.3K
YoY Change 6.87% 11.19% 12.93%
% of Gross Profit
Research & Development $1.732M $2.078M $1.678M
YoY Change -5.2% 40.78% 39.04%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.407M $2.763M $2.457M
YoY Change -2.1% 32.07% 29.69%
Operating Profit -$2.407M -$2.763M -$2.457M
YoY Change -2.1% 32.07% 29.69%
Interest Expense $7.700K $420.00 $460.00
YoY Change 1227.59% -96.57% -95.4%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.400M -$2.763M -$2.457M
YoY Change -2.39% 32.82% 30.68%
Income Tax
% Of Pretax Income
Net Earnings -$2.400M -$2.763M -$2.457M
YoY Change -2.39% 32.82% 30.4%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.22
Diluted Earnings Per Share -$188.1K -$218.7K -$194.9K
COMMON SHARES
Basic Shares Outstanding 12.73M shares 12.62M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.32M $16.46M $17.82M
YoY Change -35.92% -32.23% -30.72%
Cash & Equivalents $14.32M $16.46M $17.82M
Short-Term Investments
Other Short-Term Assets $55.70K $189.2K $193.6K
YoY Change -47.85% 97.96% 76.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.37M $16.65M $18.01M
YoY Change -35.98% -31.72% -30.29%
LONG-TERM ASSETS
Property, Plant & Equipment $72.89K $84.36K $53.69K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $72.89K $84.36K $53.69K
YoY Change 5.85% 22.52% -23.3%
TOTAL ASSETS
Total Short-Term Assets $14.37M $16.65M $18.01M
Total Long-Term Assets $72.89K $84.36K $53.69K
Total Assets $14.45M $16.74M $18.07M
YoY Change -35.85% -31.57% -30.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.867M $2.140M $1.048M
YoY Change 50.53% 93.9% 29.4%
Accrued Expenses $47.80K $47.03K $25.98K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.914M $2.187M $1.074M
YoY Change 54.39% 98.16% 32.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.85K $33.09K $25.34K
YoY Change
Total Long-Term Liabilities $20.85K $33.09K $25.34K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.914M $2.187M $1.074M
Total Long-Term Liabilities $20.85K $33.09K $25.34K
Total Liabilities $1.935M $2.220M $1.099M
YoY Change 56.07% 101.16% 35.74%
SHAREHOLDERS EQUITY
Retained Earnings -$48.91M -$46.51M
YoY Change 26.68% 28.66%
Common Stock $12.86K $12.70K
YoY Change 2.1% 0.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.51M $14.52M $16.97M
YoY Change
Total Liabilities & Shareholders Equity $14.45M $16.74M $18.07M
YoY Change -35.85% -31.57% -30.27%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.400M -$2.763M -$2.457M
YoY Change -2.39% 32.82% 30.4%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.148M -$1.311M -$2.468M
YoY Change 10.67% -6.65% 27.32%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -23.73K -65.46K -$16.67K
YoY Change 137.78% 188.24% -100.15%
NET CHANGE
Cash From Operating Activities -2.148M -1.311M -$2.468M
Cash From Investing Activities $0.00
Cash From Financing Activities -23.73K -65.46K -$16.67K
Net Change In Cash -2.172M -1.376M -$2.484M
YoY Change 11.32% -3.55% -127.65%
FREE CASH FLOW
Cash From Operating Activities -$2.148M -$1.311M -$2.468M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
189179 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
217745 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
16652748 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
20521614 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
84363 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q2 us-gaap Assets
Assets
16737111 usd
CY2021Q4 us-gaap Assets
Assets
20521614 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2186996 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1580543 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2186996 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1580543 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33092 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q2 us-gaap Liabilities
Liabilities
2220088 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12598 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60220016 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3160 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18941071 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20521614 usd
mnpr Operating Lease Weighted Average Remaining Lease Terms1
OperatingLeaseWeightedAverageRemainingLeaseTerms1
P1Y8M1D
dei Entity Central Index Key
EntityCentralIndexKey
0001645469
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12598125 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12700737 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39070
dei Entity Registrant Name
EntityRegistrantName
MONOPAR THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0463781
dei Entity Address Address Line1
EntityAddressAddressLine1
1000 Skokie Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 350
dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmette
dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60091
dei City Area Code
CityAreaCode
847
dei Local Phone Number
LocalPhoneNumber
388-0349
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
MNPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12725751 shares
CY2021Q4 us-gaap Liabilities
Liabilities
1580543 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12700737 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12598125 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
12701 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60994892 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17466 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46508036 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41288383 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
14517023 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16737111 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2078471 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1476430 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3756403 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
684877 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1303901 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
2092395 usd
us-gaap Operating Expenses
OperatingExpenses
5220534 usd
us-gaap Operating Expenses
OperatingExpenses
3987110 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2763348 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2092395 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5220534 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3987110 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
417 usd
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
12226 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
881 usd
us-gaap Share Based Compensation
ShareBasedCompensation
725825 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-28552 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
22922 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2762931 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2080169 usd
us-gaap Net Income Loss
NetIncomeLoss
-5219653 usd
us-gaap Net Income Loss
NetIncomeLoss
-3964188 usd
CY2022Q2 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
21210 usd
CY2021Q2 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-55 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
20626 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
2717 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2741721 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2080224 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5199027 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3961471 usd
CY2022Q2 mnpr Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.22
CY2021Q2 mnpr Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.17
mnpr Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.41
mnpr Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.32
CY2022Q2 mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted Total
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal
12632381 shares
CY2021Q2 mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted Total
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal
12569933 shares
mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted Total
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal
12618489 shares
mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted Total
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal
12355867 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18941071 usd
CY2022Q1 mnpr Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount
IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount
0 usd
CY2022Q1 mnpr Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount
IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount
-16666 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
499812 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2456722 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-584 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
16966911 usd
CY2022Q2 mnpr Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount
IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount
0 usd
CY2022Q2 mnpr Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount
IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount
-29655 usd
CY2022Q2 mnpr Issuance Of Common Stock Upon Exercise Of Stock Options Amount
IssuanceOfCommonStockUponExerciseOfStockOptionsAmount
41 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
357293 usd
CY2022Q2 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
35846 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-2762931 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
21210 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
14517023 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15691991 usd
CY2021Q1 mnpr Issuance Of Common Stock Under A Capital On Demandtm Sales Agreement With Jonestrading Institutional Services Llc Net Of Commissions And Fees Three Three Eight One Five Three Amount
IssuanceOfCommonStockUnderACapitalOnDemandtmSalesAgreementWithJonestradingInstitutionalServicesLlcNetOfCommissionsAndFeesThreeThreeEightOneFiveThreeAmount
10925312 usd
CY2021Q1 mnpr Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount
IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount
0 usd
CY2021Q1 mnpr Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount
IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount
-21500 usd
CY2021Q1 mnpr Issuance Of Common Stock Upon Exercise Of Stock Options Amount
IssuanceOfCommonStockUponExerciseOfStockOptionsAmount
17478 usd
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
368232 usd
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-1884019 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2774 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
25100268 usd
CY2021Q2 mnpr Issuance Of Common Stock To Non Employee Directors Pursuant To Vested Restricted Stock Units Amount
IssuanceOfCommonStockToNonEmployeeDirectorsPursuantToVestedRestrictedStockUnitsAmount
0 usd
CY2021Q2 mnpr Issuance Of Common Stock To Employees Pursuant To Vested Restricted Stock Units Net Of Taxes Amount
IssuanceOfCommonStockToEmployeesPursuantToVestedRestrictedStockUnitsNetOfTaxesAmount
-24003 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
357593 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-2080169 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-57 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
23353632 usd
us-gaap Profit Loss
ProfitLoss
-5219653 usd
us-gaap Profit Loss
ProfitLoss
-3964188 usd
us-gaap Share Based Compensation
ShareBasedCompensation
857105 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
32875 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
559959 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-72942 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4238 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3778275 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3344180 usd
mnpr Cash Proceeds From The Sales Of Common Stock Under A Capital
CashProceedsFromTheSalesOfCommonStockUnderACapital
0 usd
mnpr Cash Proceeds From The Sales Of Common Stock Under A Capital
CashProceedsFromTheSalesOfCommonStockUnderACapital
10925312 usd
mnpr Payment Of Financing And Stock Issuance Costs Other
PaymentOfFinancingAndStockIssuanceCostsOther
35846 usd
mnpr Payment Of Financing And Stock Issuance Costs Other
PaymentOfFinancingAndStockIssuanceCostsOther
0 usd
mnpr Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits
46321 usd
mnpr Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits
45503 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17478 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-82126 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10897287 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
20101 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
2634 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3840300 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7555741 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20303869 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16737109 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16463569 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24292850 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
92359 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 1 – Nature of Business and Liquidity</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Nature of Business</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Monopar Therapeutics Inc. (“Monopar” or the ”Company”) is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve quality of life for cancer patients. Monopar currently has four compounds in development: 1) Validive<sup style="vertical-align:super">®</sup> (clonidine hydrochloride mucobuccal tablet; clonidine HCI MBT), a Phase 2b/3 clinical stage, first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (“SOM”) in oropharyngeal cancer patients; 2) camsirubicin (generic name for MNPR-201, GPX-150; 5-imino-13-deoxydoxorubicin), a Phase 1b clinical stage novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; 3) MNPR-101, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for advanced cancers and severe COVID-19; and 4) an early stage camsirubicin analog, MNPR-202, for various cancers. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Liquidity</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred an accumulated deficit of approximately $46.5 million as of June 30, 2022. To date, the Company has primarily funded its operations with the net proceeds from the Company’s initial public offering of its common stock on Nasdaq, sales of its common stock in the public market through an at-the-market sales agreement, private placements of convertible preferred stock and of common stock and cash provided in the camsirubicin asset purchase transaction. Management estimates that currently available cash will provide sufficient funds to enable the Company to meet its obligations at least through September 2023. The Company’s ability to fund its future operations, including the continued clinical development of Validive and camsirubicin, is dependent upon its ability to execute its business strategy, to obtain additional funding and/or to execute collaborative research agreements. There can be no certainty that future financing or collaborative research agreements will occur in the amounts required or at a time needed to maintain operations, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The coronavirus disease (“COVID-19”) pandemic continues to affect economies and business around the world. In response to COVID-19 and its effects on clinical trials, in 2020 Monopar modified the original adaptive design Phase 3 clinical trial for its lead product candidate, Validive, to be a Phase 2b/3 clinical trial (“VOICE”) to better fit the types of trials which can enroll sufficient required patients in the current environment. This modification allowed the Company to activate the VOICE clinical trial without requiring near-term financing. To complete the VOICE clinical program, including, if required, completing a second Phase 3 confirmatory clinical trial, Monopar will require additional funding in the millions or tens of millions of dollars (depending on if the Company has consummated a collaboration or partnership or neither for Validive), which it is planning to pursue within the next 12 months. Due to many uncertainties, the Company is unable to estimate the pandemic’s financial impact or duration in light of global vaccine rollouts, treatment options and adverse new cases surging from COVID-19 variants at this time, or its potential impact on the Company’s current clinical trials, including COVID-19’s effect on drug candidate manufacturing, shipping, patient recruitment at clinical sites and regulatory agencies around the globe. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Russia-Ukraine conflict and resulting sanctions against Russia and Russian entities have increased fuel costs and may cause shipping delays and the broader economic, trade and financial market consequences are uncertain at this time, which may increase the cost of supplies for the Company’s clinical materials, may delay the manufacture of its clinical materials, may increase costs of other goods and services or make it more difficult or costly to raise additional financing, any of which could cause an adverse effect on the Company’s clinical programs and on the Company’s financial condition. </p>
CY2022Q2 mnpr Accumulated Deficit
AccumulatedDeficit
-46500000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </p>
CY2022Q2 mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
12632381 shares
CY2021Q2 mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
12569933 shares
mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
12618489 shares
mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
12355867 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2217341 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1671940 shares
CY2022Q2 mnpr Insurance Premiums Dues Subscription And Software Cost Paid In Advance
InsurancePremiumsDuesSubscriptionAndSoftwareCostPaidInAdvance
10000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents at two reputable financial institutions. As of June 30, 2022, the balance at one financial institution was in excess of the $250,000 Federal Deposit Insurance Corporation (“FDIC”) insurable limit. The Company has not experienced any losses on its deposits since inception and management believes the Company is not exposed to significant risks with respect to these financial institutions.</p>
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
16055085 usd
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
16055085 usd
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
20014205 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
20014205 usd
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 mnpr Common Stock Aggregate Offering Price Description
CommonStockAggregateOfferingPriceDescription
4870000 usd
CY2022Q2 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
35846 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12700737 shares
mnpr Aggregate Stock Option Purchase Of Shares
AggregateStockOptionPurchaseOfShares
25000 shares
mnpr Description Of Exercise Price
DescriptionOfExercisePrice
exercise prices ranging from $2.48 to $2.66 per share which vest over 4 years
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1258577 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.47
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
403476 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.27
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
115151 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.49
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2913 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1543989 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
578064 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
205933 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.54
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40532 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.001
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1875588 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
575424 shares
mnpr Weighted Average Exercise Price Unvested Options Outstanding Expected To Vest
WeightedAverageExercisePriceUnvestedOptionsOutstandingExpectedToVest
4.06
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1875588 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1300164 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
25000 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
105000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
578064 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
301476 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.00
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.64
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
260251 usd
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
302395 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
552578 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
558018 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1200000 usd
CY2022Q2 mnpr Weighted Average Exercise Price
WeightedAverageExercisePrice
4.19
CY2022Q2 mnpr Weighted Average Vested Exercise Price
WeightedAverageVestedExercisePrice
4.25
CY2022Q2 mnpr Weighted Average Stock Options Expected To Vest
WeightedAverageStockOptionsExpectedToVest
4.06
CY2022Q2 mnpr Unamortized Unvested Balance Of Stock Base Compensation
UnamortizedUnvestedBalanceOfStockBaseCompensation
290000 usd
mnpr Unamortized Unvested Balance Of Stock Base Compensation Period
UnamortizedUnvestedBalanceOfStockBaseCompensationPeriod
P2Y9M18D
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
11995 usd
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
14571 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
23077 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
28033 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
25428 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4635 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
80125 usd
mnpr Schdule Of Weighted Average Remaining Lease Term And Discount Rate
SchduleOfWeightedAverageRemainingLeaseTermAndDiscountRate
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Lease term:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt">Operating lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1.67 years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">—</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Discount rate:</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:11.25pt">Operating lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.50</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">—</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
50856 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8476 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
84760 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650 pure
CY2022Q2 mnpr Operating Lease Right Of Use Asset Non Current
OperatingLeaseRightOfUseAssetNonCurrent
84363 usd
CY2021Q2 mnpr Operating Lease Right Of Use Asset Non Current
OperatingLeaseRightOfUseAssetNonCurrent
0 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
47033 usd
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33092 usd
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
80125 usd
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
0 usd

Files In Submission

Name View Source Status
0001654954-22-011015-index-headers.html Edgar Link pending
0001654954-22-011015-index.html Edgar Link pending
0001654954-22-011015.txt Edgar Link pending
0001654954-22-011015-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mnpr-20220630.xsd Edgar Link pending
mnpr_10q.htm Edgar Link pending
mnpr_10qimg1.jpg Edgar Link pending
mnpr_ex311.htm Edgar Link pending
mnpr_ex312.htm Edgar Link pending
mnpr_ex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mnpr-20220630_cal.xml Edgar Link unprocessable
mnpr-20220630_def.xml Edgar Link unprocessable
mnpr-20220630_lab.xml Edgar Link unprocessable
mnpr-20220630_pre.xml Edgar Link unprocessable
mnpr_10q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending